MapLight Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
MapLight Therapeutics, Inc. (MPLT) holds an ST Score of 48.1 out of 100 (C+), with its strongest factor being Financial Strength (A+) and its weakest Momentum (D). Analysts rate MPLT Buy across 7 ratings with a $29.20 average price target (+1.7% vs the current $10.92).
- Strongest
- Financial StrengthA+
- Weakest
- MomentumD
All factor grades
- Financial StrengthA+
- ForecastB+
- GrowthB-
- ValuationC+
- ProfitabilityC-
- MomentumD
- Piotroski2/9
Contact
MPLT stock: frequently asked questions
What is MPLT's ST Score?
MapLight Therapeutics, Inc. (MPLT) has an ST Score of 48.1 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is MPLT a buy, sell, or hold?
Wall Street's consensus rating on MPLT is Buy based on 7 analyst ratings. Our own ST Score grades it C+ (48.1/100). This is data, not investment advice — always do your own research.
What is MPLT's valuation grade?
MapLight Therapeutics, Inc. (MPLT) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is MPLT's growth grade?
MapLight Therapeutics, Inc. (MPLT) earns a growth grade of B-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is MPLT's profitability grade?
MapLight Therapeutics, Inc. (MPLT) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is MPLT's financial strength grade?
MapLight Therapeutics, Inc. (MPLT) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for MPLT?
The average analyst price target for MapLight Therapeutics, Inc. (MPLT) is $29.20 from 7 analysts, which is +1.7% versus the recent price of $10.92.
What is MPLT's Piotroski score?
MapLight Therapeutics, Inc. (MPLT) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.